Inicio › Cáncer de páncreas › Carolina del Norte › Durham
Ensayos clínicos de Cáncer de páncreas en Durham, NC
24 estudios para Cáncer de páncreas buscan participantes en centros de Durham y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
The Vanguard Study: Testing a New Way to Screen for Cancer
ReclutandoSe aceptan voluntarios sanos
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
A Study of PHN-012 in Patients With Advanced Solid Tumors
ReclutandoFase 1
- PHN-012-001 Site, Durham
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
ReclutandoFase 3
- Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
ReclutandoEstudio observacional
- Research Site, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ReclutandoFase 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · A 10 mi de distancia
- University of North Carolina Hospitals at Hillsborough, Hillsborough · A 13 mi de distancia
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
ReclutandoFase 3
- Duke Cancer Center, Durham
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
ReclutandoFase 3
- Investigative Site US035, Chapel Hill · A 10 mi de distancia
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
ReclutandoFase 1/2
- Duke University Medical Center, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
ReclutandoFase 2
- Local Institution - 0100, Durham
Promoting CT Engagement for Pancreatic Cancer With App
Reclutando
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
ReclutandoEstudio observacional
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
- University of North Carolina-Hillsborough Campus, Hillsborough · A 13 mi de distancia
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
ReclutandoFase 2
- University of North Carolina, Chapel Hill · A 10 mi de distancia
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
ReclutandoFase 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · A 10 mi de distancia
- University of North Carolina, Chapel Hill · A 10 mi de distancia
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
ReclutandoFase 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
ReclutandoFase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
ReclutandoFase 2
- Duke University Medical Center, Durham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
ReclutandoFase 1
- Duke Cancer Institute /ID# 276267, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
ReclutandoFase 1
- Research Site, Durham
Autologous CAR-T Cells Targeting B7-H3 in PDAC
ReclutandoFase 1
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
ReclutandoFase 1
- Duke Cancer Center, Durham
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
ReclutandoFase 1/2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
ReclutandoFase 2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · A 10 mi de distancia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Chapel Hill · A 10 mi de distancia
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
ReclutandoFase 2
- University of North Carolina, Chapel Hill · A 10 mi de distancia
Más información sobre Cáncer de páncreas en MedlinePlus
Ensayos de Cáncer de páncreas en otras ciudades
- Houston, TX61 estudios
- New York City, NY60 estudios
- Boston, MA43 estudios
- Nashville, TN39 estudios
- Los Angeles, CA35 estudios
- St. Louis, MO33 estudios
- Arlington, VA33 estudios
- Baltimore, MD31 estudios
- San Antonio, TX31 estudios
- Philadelphia, PA26 estudios
- Tampa, FL26 estudios
- San Diego, CA24 estudios
Otros estudios en Durham
- Cáncer de seno64 estudios
- Cáncer (todos los tipos)58 estudios
- Cáncer de pulmón de células no pequeñas39 estudios
- Mieloma múltiple37 estudios
- Leucemia mielógena aguda33 estudios
- Cáncer metastásico33 estudios
- Cáncer de próstata32 estudios
- Cáncer de pulmón32 estudios
- Cáncer del colon y del recto28 estudios
- Cáncer de ovario27 estudios
- Leucemia linfocítica crónica27 estudios
- Fallo cardíaco26 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.